Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01BX001002-09A1 |
| Title: | Role of Cyr61/CCN1 in Pancreatic Cancer Progression and Therapy |
| Principal Investigator: | Snigdha Banerjee |
| Location: | Kansas City, MO |
| Congressional District Code: | 5 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | October 2020 - September 2024 |
| FY 2021 Funding Amount: | $341,734 |
| Total Award Amount (all years): |
$1,425,682 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Pancreatic ductal adenocarcinoma (PDAC) remains one of the leading sources of cancer mortality worldwide, including US Veterans. An initial response to chemotherapy, such as Gemcitabine (GEM) is often followed by emergent resistance reflecting an urgent need for targeted therapies. Our studies have found that CYR61 is a druggable PDAC driver, and it can be suppressed by Zoledronic acid (ZA) under tissue culture conditions. Regrettably, the weak availability in the target tissue limits the therap... |